Health1 min read

STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more

By · Via STAT Health · Published by Everything Blog

In short

Merck has formed a strategic discovery pact with Isomorphic Labs to identify small molecule candidates targeting an undisclosed cancer. Isomorphic will leverage its proprietary design engine alongside Merck's lab data, while Merck manages all subsequent preclinical, clinical, and commercialization steps. In a separate regulatory milestone, the FDA approved Sanofi’s Infilbray as the first drug for the neurological aspects of type 3 Gaucher disease. This clearance applies to patients weighing 15 kilograms or more based on clinical trial evidence from 43 stabilized individuals.

Key points

  • Merck is leveraging computational AI design to accelerate its small molecule oncology dru…: Merck is leveraging computational AI design to accelerate its small molecule oncology drug pipeline.
  • Infilbray offers the first approved treatment option for the brain and nervous system man…: Infilbray offers the first approved treatment option for the brain and nervous system manifestations of type 3 Gaucher disease.
  • Sanofi secured federal approval following a late-stage study of 43 patients aged 12 and o…: Sanofi secured federal approval following a late-stage study of 43 patients aged 12 and older with stabilized non-neurological symptoms.

Sources checked by our analysis pipeline: 1

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they have finished keeping passersby at bay and are now happily snoozing in their respective corners. As for us, we are firing up the trusty kettle for another cup of stimulation. Our choice today is peppermint, an old standby from our pantry. Of course, you are invited to join us. Meanwhile, here is the latest menu of tidbits. As always, do keep in touch. And best of luck today. …

Merck and Isomorphic Labs, the artificial intelligence drug designer built on a Nobel-winning technology that can model how molecules will bind to proteins, are entering into a research collaboration to discover small molecule candidates for an undisclosed oncology target of “strategic importance,” STAT reports. The partnership — only the latest such deal between a pharma giant and Isomorphic — will join Isomorphic’s proprietary drug design engine and existing wet lab…

Health